Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Short-term Investments (2023 - 2025)

Immunome (IMNM) has disclosed Short-term Investments for 3 consecutive years, with $124.2 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Short-term Investments rose 9.86% year-over-year to $124.2 million, compared with a TTM value of $124.2 million through Jun 2025, up 9.86%, and an annual FY2024 reading of $74.0 million, up 87.4% over the prior year.
  • Short-term Investments was $124.2 million for Q2 2025 at Immunome, up from $59.7 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $124.2 million in Q2 2025 and bottomed at $39.5 million in Q4 2023.
  • Average Short-term Investments over 3 years is $76.4 million, with a median of $74.0 million recorded in 2024.
  • The sharpest move saw Short-term Investments skyrocketed 87.4% in 2024, then increased 9.86% in 2025.
  • Year by year, Short-term Investments stood at $39.5 million in 2023, then skyrocketed by 87.4% to $74.0 million in 2024, then soared by 67.89% to $124.2 million in 2025.
  • Business Quant data shows Short-term Investments for IMNM at $124.2 million in Q2 2025, $59.7 million in Q1 2025, and $74.0 million in Q4 2024.